Eagle Pharmaceuticals, Inc. (EGRX) Trades at $59.02 After Triangle; Advent Claymore Convertible Securities & Income Fund II (AGC)’s Sentiment Is 0.65

The stock decreased 1.14% or $0.07 during the last trading session, reaching $6.07. About 212,655 shares traded or 31.77% up from the average. Advent Claymore Convertible Securities & Income Fund II (AGC) has risen 13.10% since January 31, 2017 and is uptrending. It has underperformed by 3.60% the S&P500.

Eagle Pharmaceuticals, Inc. (EGRX) formed triangle with $56.66 target or 4.00% below today’s $59.02 share price. Eagle Pharmaceuticals, Inc. (EGRX) has $880.67 million valuation. The stock decreased 4.85% or $3.01 during the last trading session, reaching $59.02. About 251,167 shares traded or 8.37% up from the average. Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) has risen 79.40% since January 31, 2017 and is uptrending. It has outperformed by 62.70% the S&P500.

Saba Capital Management L.P. holds 1.71% of its portfolio in Advent Claymore Convertible Securities & Income Fund II for 2.70 million shares. Shaker Financial Services Llc owns 201,174 shares or 0.66% of their US portfolio. Moreover, Robinson Capital Management Llc has 0.53% invested in the company for 188,394 shares. The Illinois-based Rivernorth Capital Management Llc has invested 0.29% in the stock. Sit Investment Associates Inc, a Minnesota-based fund reported 1.13 million shares.

Among 4 analysts covering Eagle Pharma (NASDAQ:EGRX), 3 have Buy rating, 1 Sell and 0 Hold. Therefore 75% are positive. Eagle Pharma has $119 highest and $37.0 lowest target. $72.50’s average target is 22.84% above currents $59.02 stock price. Eagle Pharma had 20 analyst reports since July 29, 2015 according to SRatingsIntel. On Friday, July 14 the stock rating was maintained by RBC Capital Markets with “Buy”. William Blair maintained the stock with “Outperform” rating in Wednesday, November 2 report. Mizuho maintained Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) on Friday, February 26 with “Buy” rating. The stock of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) earned “Buy” rating by Mizuho on Wednesday, October 26. As per Thursday, November 3, the company rating was upgraded by Mizuho. Mizuho downgraded Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) rating on Monday, January 9. Mizuho has “Underperform” rating and $64 target. Mizuho downgraded the shares of EGRX in report on Monday, June 20 to “Neutral” rating. The company was maintained on Monday, October 2 by RBC Capital Markets. As per Wednesday, December 9, the company rating was initiated by Mizuho. On Tuesday, July 25 the stock rating was maintained by Piper Jaffray with “Buy”.

Analysts await Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) to report earnings on March, 7. They expect $1.19 EPS, down 66.19% or $2.33 from last year’s $3.52 per share. EGRX’s profit will be $17.76M for 12.40 P/E if the $1.19 EPS becomes a reality. After $1.07 actual EPS reported by Eagle Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 11.21% EPS growth.